Prognosis of human pancreatic adenocarcinoma: Review of clinical and histopathological variables and possible uses of new molecular methods

European Journal of Surgery

Volumn 165, Issue 4, 1999, Pages 292-306

  Eskelinen, Matti J ^a,b   Haglund, Ulf H ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

A review; Pancreatic cancer; Prognosis

Indexed keywords

CYCLINE; DNA; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

APOPTOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; HISTOPATHOLOGY; HUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADENOCARCINOMA; EUROPE; GENES, TUMOR SUPPRESSOR; HUMANS; INCIDENCE; NORTH AMERICA; ONCOGENES; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 0032769459     PISSN: 11024151     EISSN: None     Source Type: Journal    
DOI: 10.1080/110241599750006811     Document Type: Review

References (174)

1. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K. Mitotic indexes as prognostic predictors in female breast cancer. J Cancer Res Clin Oncol 1992; 118: 75-81.
2. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjänen K. Prognostic value of Ki-67 expression in renal cell carcinomas. Eur Urol 1997; 31: 350-355.
3. Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjänen K. The value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997; 32: 410-415.
4. Abe M, Shibamoto Y, Takahashi M, et al. Intraoperative radiotherapy in carcinoma of the stomach and pancreas. World J Surg 1987; 11: 459-464.
5. Alanen K, Joensuu H, Klemi P, et al. Clinical significance of nuclear DNA content in pancreatic carcinoma. J Pathol 1990; 160: 313-320.
6. Allema DC, Bose KK, Hruban RH, et al. Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy. Ann Surg 1991; 214: 648-656.
7. Allison DC, Bose KK, Hruban RH, et al. Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy. Ann Surg 1991; 214: 648-656.
8. Almoguerra C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554.
9. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 1992; 359: 423-426.
10. Andren-Sandberg A, Ihse I. Factors influencing survival after total pancreatectomy in patients with pancreatic cancer. Ann Surg 1983; 198: 605-610.
11. Appelquist P, Viren M, Minkkinen J, Kajanti M, Kostiainen S, Rissanen P. Operative finding, treatment, and prognosis of carcinoma of the pancreas: An analysis of 267 cases. J Surg Oncol 1983; 23: 143-150.
12. Baak JPA, Oort J. A manual of morphometry in diagnostic pathology. Springer-Verlag, Berlin, 1983.
13. Baisch H, Klöppel G, Reinke B. DNA ploidy and cell-cycle analysis in pancreatic and ampullary carcinoma: flow cytometric study of formalin-fixed paraffin-embedded tissue. Virchows Arch [Pathol Anat] 1990; 417: 145-150.
14. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076-1082.
15. Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells Jr SA, Goodfellow PJ. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes Cancer 1995; 14: 189-195.
16. Bartsch D, Shevlin DW, Gallery MP, Norton JP, Wells Jr SA, Goodfellow PJ. Reduced survival in patients with ductal pancreatic adenocarcinomas associated with CDKN2 mutation. J Natl Cancer Inst 1996; 88: 680-682.
17. Baumel H, Huguier M, Manderscheid JC, Fabre JM, Houry S, Fagot H. Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br J Surg 1994; 81: 102-107.
18. Bose KK, Allison DC, Hruban RH, et al. A comparison of flow cytometric and absorption cymetric DNA values as prognostic indicators for pancreatic carcinoma. Cancer 1993; 71: 691-700.
19. Braasch JW, Rossi RL, Watkins Jr E, et al. Pyloric and gastric preserving pancreatic resection. Experience with 87 patients. Ann Surg 1986; 206: 411-417.
20. Bramhall SR, Allum WH, Jones AG, Allwood A, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995; 82: 111-115.
21. Bravo R, Frank R, Blundell PA. Cyclin/PCNA is the auxilliary protein of DNA polymerase-delta. Nature 1987; 326: 515-517.
22. Brown PC, Hart MJ, White TT. Pancreatic lymphoma, diagnosis and management. Int J Pancreatol 1987; 2: 93-100.
23. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990; 17: 489-503.
24. Böttger T, Zech J, Weber W, et al. Relevant factors in the prognosis of ductal pancreatic carcinoma. Acta Chir Scand 1990; 156: 781-788.
25. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54: 3568-3573.
26. Cameron JL, Crist D, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161: 120-124.
27. Casey G, Yamanaka Y, Friess H, et al. P53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993; 69: 151-160.
28. Caspersson T-B, Schultz J. Nucleic acid metabolism of the chromosomes in relation to gene reproduction. Nature 1938; 142: 294-297.
29. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-363.
30. Collan Y. Reproducibility, the neglected cornerstone of medical diagnostics. In: Collan Y, Romppanen T, eds. Morphometry in morphological diagnosis. Kuopio: Kuopio University Press, 1982: 5-21.
31. Collan Y, Torkkeli T, Pesonen E, Jantunen E, Kosma VM. Application of morphometry in tumour pathology. Anal Quant Cytol Histol 1987; 9: 79-88.
32. Condie JD, Nagpal S, Peebles SA. Surgical treatment for ductal adenocarcinoma of the pancreas. Surg Gynecol Obstet 1989; 168: 437-445.
33. Connolly MM, Dawson PJ, Michelassi F, et al. Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 1987; 206: 366-370.
34. Coons AH, Kaplan MH. Localization of antigen in tissue cells II. Improvements in a method for the detection of antigen by means of fluorescent antibody. J Exp Med 1950; 91: 1-4.
35. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987; 206: 358-365.
36. Cubilla AL, Fitzgerald PJ, Fortner JG. Pancreas cancer-duct cell adenocarcinoma: survival in relation to site, size, stage and type of therapy. J Surg Oncol 1978; 10: 465-482.
37. Cubilla AL, Fitzgerald PJ. Cancer (non-endocrine) of the pancreas. A suggested classification. In: Fitzgerald PJ, Morrison AB, eds. The pancreas. Baltimore: Williams & Wilkins, 1980: 82-110.
38. Cuzick J, Babiker AG. Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. Int J Cancer 1989; 43: 415-421.
39. Devilee P, Cornelisse CJ. Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1994; 118: 113-130.
40. DiGiuseppe JA, Hruban RH, Goodman SN, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994; 101: 684-688.
41. Dunn E. The impact of technology and improved perioperative management upon survival from carcinoma of the pancreas. Surg Gynecol Obstet 1987; 164: 237-244.
42. Ekbom A, McLaughlin JK, Karlsson BM, et al. Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst 1994; 86: 625-627.
43. Erisman MD, Litwin S, Keidan RD, Comis RL, Astrin SM. Noncorrelation of the expression of the c-myc oncogene in colorectal carcinoma with recurrence of disease or patient survival. Cancer Res 1988; 48: 1350-1355.
44. Eskelinen M, Lipponen P, Collan Y, et al. Cancer of the pancreas: Clinical stage, histological grade, surgical therapy and survival. Surg Res Comm 1991; 10: 9-14.
45. Eskelinen M, Lipponen P, Collan Y, et al. Relationship between DNA ploidy and survival in patients with exocrine pancreatic cancer. Pancreas 1991; 6: 90-95.
46. Eskelinen M, Lipponen P, Marin S, et al. Prognostic factors in human pancreatic cancer, with special reference to quantitative histology. Scand J Gastroenterol 1991; 26: 483-490.
47. Eskelinen M, Lipponen P, Majapuro R, Syrjänen K. Prognosis of prostatic cancer assessed by means of quantitative histology. Eur Urol 1991; 19: 274-278.
48. Eskelinen M, Lipponen P, Marin S, et al. DNA ploidy, S-phase fraction and G2 fraction as prognostic determinants in human pancreatic cancer. Scand J Gastroenterol 1992; 27: 39-43.
49. Eskelinen M, Lipponen P. A review of prognostic factors in human pancreatic adenocarcinoma. Cancer Detec Prev 1992; 16: 287-295.
50. Farrow DC, Davis S. Diet and risk of pancreatic cancer in men. Am J Epidemiol 1990; 132: 423-431.
51. Farrow DC, Davis S. Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol and coffee. Int J Cancer 1990; 45: 816-820.
52. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68-73.
53. Ghadirian P, Simard A, Baillargeon J. Tobacco, alcohol, and coffee and cancer of the pancreas. Cancer 1991; 67: 2664-2670.
54. Gibson JB, Sobin LH Histological typing of tumours of the liver, biliary tract and pancreas. International Histological Classification of tumours, No. 20. Geneva: WHO, 1978: 18-37.
55. Gordis L, Gold EB. Epidemiology of pancreatic cancer. World J Surg 1984; 8: 808-821.
56. Griffin JE, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic cancer. Cancer 1990; 66: 56-61.
57. Grunewald K, Lyons J, Fröhlich A, et al. High frequency of Ki-ras codon12 mutations in pancreatic adenocarcinoma. Int J Cancer 1989; 43: 1037-1041.
58. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987; 60: 2284-2303.
59. Haapasalo H, Collan Y, Atkin NB, Pesonen E, Seppä A. Prognosis of ovarian carcinomas: prediction by histoquantitative techniques. Histopathology 1989; 15: 167-178.
60. Haapasalo H, Collan Y, Pesonen E. Volume corrected mitotic index (M/V index)- the standard of mitotic activity in neoplasms. Pathol Res Pract 1989; 185: 551-554.
61. Hahn SA, Schutte M, Shamsul Hoque ATM, et al. DPC4, a candidate tumour suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353.
62. Hakulinen T, Anderson AA, Möller B, et al. Trends in cancer incidence in the Nordic countries. Acta Pathol Microbiol Scand [B] 1986; 94 (suppl 288): 50-53.
63. Hann SR, King MW, Bentley DL, Anderson CW, Eisenman RN. A non-AUG translational initiaton in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphoma. Cell 1988; 52: 185-195.
64. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
65. Harris CC. At the crossroads of molecular carcinogenesis and risk assessment. Science 1993; 262: 1980-1981.
66. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-1335.
67. Hermanek P, Scheibe O, Spiessl B, Wagner G. UICC/TNM classification of malignant tumours. 4th ed. Berlin: Springer-Verlag, 1992.
68. Hermreck AS, Thomas CY, Friesen SR. Importance of pathologic staging in the surgical management of adenocarcinoma of the exocrine pancreas. Am J Surg 1974; 12: 653-657.
69. Herrera MF, van Heerden JA, Katzman JA, Weiland LH, Nagorney DM, Ilstrup LH. Evaluation of DNA nuclear pattern as a prognostic determinant in resected pancreatic ductal adenocarcinoma. Ann Surg 1992; 215: 120-124.
70. Hirata K, Sato T, Mukaiya M, et al. Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg 1997; 132: 771-776.
71. Hirayama T. Epidemiology of pancreatic cancer in Japan. Jpn J Clin Oncol 1989; 19: 208-215.
72. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
73. Howe GR, Jain M, Miller AB. Dietary factors and risk of pancreatic cancer: results of a Canadian population-based case-control study. Int J Cancer 1990; 45: 604-608.
74. Howe GR, Jain M, Burch JD, Miller AB. Cigarette smoking and cancer of the pancreas: evidence from a population-based case-control study in Toronto, Canada. Int J Cancer 1991; 47: 323-328.
75. Hruban RH, van Mansfield ADM, Offerhaus GJA, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. Am J Pathol 1993; 143: 545-554.
76. Huang L, Goodrow TL, Zhang SY, et al. Deletion and mutation analyses of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinoas. Cancer Res 1996; 56: 1137-1141.
77. Huovinen R, Collan Y. Cell loss in dimethylbenz(a)anthracene-induced rat mammary carcinoma treated with toremifene and ovariectomy. Tumour Biol 1994; 15: 345-353.
78. Hyöty M, Visakorpi T, Kallioniemi O-P, Mattila J, Laippala P, Nordback I. Prognostic value of analysis of DNA in pancreatic adenocarcinoma by flow cytometry. Eur J Surg 1991; 157: 595-600.
79. Kairaluoma M, Partio E, Stahlberg M, et al. Pancreatic and periampullary carcinoma. Ann Chir Gynaecol 1984; 73: 199-205.
80. Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer: assessment of prognosis by clinical presentation. Cancer 1985; 56: 397-402.
81. Kalthoff H, Schmiegel W, Roeder C, et al. p53 and K-ras alterations in pancreatic epithelial lesions. Oncogene 1993; 8: 289-298.
82. Klempnauer J, Ridder GJ, Bektas H, Pichlmayer R. Surgery for exocrine pancreatic cancer- who are the 5- and 10-year survivors? Oncology 1995; 52: 353-359.
83. Klöppel G, Sosnowski J, Eichfuss H-P, et al. Aktuelle aspekte des pankreaskarzinoms. Klinische und morphologische analyse zur diagnostik und therapie. Dtsch Med Wochenschr 1979; 104: 1801-1805.
84. Klöppel G, Kern HF, von Bulow M. Human pancreatic adenocarcinoma grown in nude mice: an analysis of their structural and biological features. Digestion 1982; 25: 44.
85. Klöppel G, Maillet B. Classification and staging of pancreatic nonendocrine tumours. Radiol Clin North America 1989; 27: 105-119.
86. Kobari M, Sunamura M, Ohasi O, Saitoh Y, Yusa T, Matsuno S. The usefulness of Japanese staging in the prognosis of patients treated operatively for adenocarcinoma of the head of the pancreas. J Am Coll Surg 1996; 182: 24-32.
87. Kotake T, Saiki S, Kinouchi T, Shiku H, Nakayama E. Detection of the c-myc gene product in urinary bladder cancer. Jpn J Cancer Res 1990; 81: 1198-1201.
88. Kummerle F, Ruckert K. The role of surgical treatment in pancreatic carcinoma. Dig Dis 1986; 4: 33-42.
89. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification and sequence. Science 1987; 235: 1394-1399.
90. Lemoine NR, Jain S, Hughes CM, et al. K-ras oncogene activation in preinvasive pancreatic adenocarcinoma. Gastroenterology 1992; 102: 230-236.
91. Levine AJ. The road to the discovery of the p53 protein. The Steiner Cancer Price Award Lecture. Int J Cancer 1994; 56: 775-776.
92. Linder S, Parrado C, Falkmer UG, Blåsjö M, Sundelin P, von Rosen A. Prognostic significance of Ki-67 antigen and p53 protein expression in pancreatic duct carcinomas: a study of the monoclonal antibodies MIB-and DO-7 in formalin-fixed paraffin-embedded tumour material. Br J Cancer 1997; 76: 54-59.
93. Lipponen PK, Eskelinen MJ. Volume corrected mitotic index and mitotic activity index in transitional cell bladder cancer. Eur Urol 1990; 18: 258-262.
94. Lipponen PK, Eskelinen MJ, Collan Y, et al. Volume corrected mitotic index (M/V index) in human pancreatic cancer: relation to histological grade, clinical stage, and prognosis. Scand J Gastroenterol 1990; 25: 548-554.
95. Lipponen P, Eskelinen M, Collan Y. Nuclear morphometry in human pancreatic adenocarcinoma; relation to histological grade, clinical stage and survival. Ital J Gastroenterol 1990; 22: 124-128.
96. Lipponen P, Kosma VM, Collan Y, Kulju T, Kosunen O, Eskelinen M. Potential of nuclear morphometry and volume corrected mitotic index (M/V index) in grading transitional cell carcinoma of the urinary bladder. Eur Urol 1990; 17: 333-337.
97. Lipponen P, Eskelinen M. Cell proliferation of transitional cell bladder tumours determined by PCNA/Cyclin immunostaining and its prognostic value. Br J Cancer 1992; 66: 171-176.
98. Lipponen P, Eskelinen M, Hietala K, Syrjänen K. Expression of proliferating cell nuclear antigen (PC 10), p53 and c-erbB-2 in renal adenocarcinoma. Int J Cancer 1994; 57: 275-280.
99. Lipponen P, Pietiläinen T, Kosma V-M, Aaltomaa S, Eskelinen M, Syrjänen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995; 177: 49-55.
100. Lipponen P, Eskelinen M, Syrjänen K. Expression of tumour-suppressor gene Rb, apoptosis suppressing protein bcl-2 and c-myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer 1995; 71: 863-867.
101. Lipponen P, Aaltomaa S, Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours. Histopathology 1996; 28: 135-140.
102. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328: 1433-1437.
103. Lundin J, Nordling S, von Boguslawsky K, Roberts PJ, Haglund C. Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res 1995; 15: 2659-2668.
104. Lundin J, Nordling S, von Boguslawsky K, Roberts PJ, Haglund C. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 1996; 53: 104-111.
105. Lygidakis NJ, van der Hyde MN, Houthoff HJ, et al. Resectional surgical procedures for carcinoma of the head of the pancreas. Surg Gynecol Obstet 1989; 168: 157-165.
106. Manabe T, Ohshio G, Baba N, et al. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 1989; 64: 1132-1137.
107. Mäkinen K, Nuutinen P, Eskelinen M, Kosma V-M, Alhava E. Sapphire probe versus bare fiber in interstitial laser hyperthermia (ILH). An experimental study with Wistar rats. Anticancer Res 1994; 14: 1023-1026.
108. Mäkinen K, Hakala T, Lipponen P, Alhava E, Eskelinen M. Expression of apoptosis supressing protein bcl-2 and p53 in human pancreatic cancer. Anticancer Res 1998; 18: 615-618.
109. Mannell A, Van Heerden JA, Weiland LnH, et al. Factors influencing survival after resection for ductal adenocarcinoma of the pancreas. Ann Surg 1986; 203: 403-407.
110. Marcu KB, Bossone SA, Patel AJ. Myc function and regulation. Annu Rev Biochem 1992; 61: 809-860.
111. Mariani-Constantini R, Merlo G, Frati L. Genomic alterations in human breast cancer: A review. Tumori 1989; 75: 311-320.
112. Marx J. How p53 suppresses cell growth. Science 1993; 262: 1644-1645.
113. Marx J. How cells cycle towards cancer. Science 1994; 263: 319-321.
114. Matsuno S, Sato S. Surgical treatment for carcinoma of the pancreas. Am J Surg 1986; 152: 499-504.
115. McCormick D, Chong H, Hobbs C, Datta C, Hall PA. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB 1. Histopathology 1993; 22: 355-360.
116. Meikranzt W, Schlegel R. Apoptosis and the cell cycle. J Cell Biochem 1995; 58: 160-17.
117. Michelassi F, Erroi F, Dawson PJ, et al. Experience with 647 consecutive tumours of the duodenum, ampulla, head of the pancreas, and distal common bile duct. Ann Surg 1989; 210: 544-556.
118. Mills PK, Beeson WL, Abbey DE, Fraser GE, Phillips RL. Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists. Cancer 1988; 61: 2578-2585.
119. Morohoshi T, Held G, Klöppel G. Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases. Histopathology 1983; 7: 645-661.
120. Morris GF, Bischoff JR, Mathews MB. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc Natl Acad Sci USA 1996; 93: 895-899.
121. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic andenocarcinoma. Cancer Res 1997; 57: 2140-2143.
122. Nix GAJJ, Dubelman C, Srivastava ED, Wilson JHP, Boender J, de Jong FE. Prognostic implications of the localization of carcinoma in the head of the pancreas. Am J Gastroenterol 1991; 86: 1027-1032.
123. Nuutinen P, Eskelinen M, Surakka M, Marin S, Alhava E. Low power interstitial hyperthermia in the treatment of ductal carcinoma of the pancreas; an experimental study with Syrian golden hamsters. Lasers Med Science 1992; 7: 45-48.
124. Ozbun MA, Butel JS. Tumour suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res 1995; 66: 71-141.
125. Park CS, Wiebke EA, Sidner RA, et al. The role of flow cytometric DNA analysis in determining prognosis of resectable ductal adenocarcinoma of the pancreas. Am Surg 1996; 62: 609-616.
126. Pasanen P, Eskelinen M, Vornanen M, Partanen K. Pancreatic lymphoma. Ann Chir Gynaecol 1993; 82: 207-209.
127. Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-1560.
128. Pietiläinen T, Lipponen P, Aaltomaa S, Kosma V-M, Eskelinen M, Syrjänen K. Expression of p53 protein has no prognostic value in breast cancer. J Pathol 1995; 177: 225-232.
129. Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma V-M, Syrjänen K. Expression of c-myc protein in breast cancer as related to established prognostic factors and survival. Anticancer Res 1995; 15: 959-964.
130. Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma V-M, Syrjänen K. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 1996; 122: 687-692.
131. Pollard HM, Anderson WAD, Brooks FP, et al. Staging of cancer of the pancreas. Cancer of the Pancreas Task Force. Cancer 1981; 47: 1631-1637.
132. Ponten J, Holmberg L, Trichopoulos D, et al. Biology and natural history of breast cancer. Int J Cancer 1990; 5 (suppl): 5-21.
133. Porschen R, Remy U, Bevers G, Schauseil S, Hengels KJ, Borchard F. Prognostic significance of DNA ploidy in adenocarcinoma of the pancreas. A flow cytometric study of paraffin-embedded specimens. Cancer 1993; 71: 3846-3850.
134. Rosenberg JM, Welch JP, Macaulay WP. Cancer of the head of the pancreas: an institutional review with emphasis on surgical therapy. J Surg Oncol 1985; 28: 217-221.
135. Rozenblum E, Schutte M, Goggins M, et al. Tumour-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-1734.
136. Rugge M, Sonego F, Sessa F, et al. Nuclear DNA content and pathology in radically treated pancreatic carcinoma. The prognostic significance of DNA ploidy, histology and nuclear grade. Cancer 1996; 74: 459-466.
137. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein Szanto AJ. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumour-suppressor genes. Oncogene 1992; 7: 1503-1511.
138. Sakorafas GH, Lazaris A, Tsiotou AG, Goullias G, Glinatsis MT, Golematis BC. Oncogenes in cancer of the pancreas. Eur J Surg Oncol 1995; 21: 251-253.
139. Sawhney N, Hall PA. Ki67-structure, function and new antibodies (editorial). J Pathol 1992; 168: 161-162.
140. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534-1543.
141. Schlichting E, Clausen OPF, Hanssen AS, Buanes TA. Ploidy and survival in resectable pancreatic cancers. Eur J Surg 1993; 159: 229-233.
142. Setälä L, Kosma V-M, Lipponen A, et al. Clinical relevance of p53 index and expression of proliferating cell nuclear antigen and Ki-67 in gastric cancer. J Cancer Res Clin Oncol 1998; 124: 497-502.
143. Silverberg E, Lubera JA. Cancer statistics. Cancer J Clin 1989; 3: 3-39.
144. Silverman DT, Dunn JA, Hoover RN, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1994; 86: 1510-1516.
145. Silvestrini R, Veneroni S, Daidone MG, et al. The bcl-2 protein: a prognostic indicator strongly related to p53 proteins in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
146. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445-1449.
147. Suzuki T, Takano Y. Comparative immunohistochemical studies of p53 and proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions in pancreatic duct call carcinomas. Jpn J Cancer Res 1993; 84: 1072-1077.
148. Tada M, Omata M, Kawai S, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53: 2472-2474.
149. Takada T, Yasuda H. A search for the prognostic factors in cancer of the pancreatic head: the significance of the DNA ploidy pattern. Surg Oncol 1995; 4: 237-243.
150. Thompson GB, van Heerden JA, Grant GS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty year experience. Surgery 1988; 104: 1011-1017
151. Trede M. The surgical treatment of pancreatic carcinoma. Surgery 1985; 97: 28-35.
152. Trede M, Schwall S, Saeger H. Survival after pancreaticoduodenectomy. Ann Surg 1990; 211: 447-458.
153. Tsuchiya R, Tomioka T, Izawa K. Collective review of small carcinomas of the pancreas. Ann Surg 1986; 203: 77-84.
154. Tsuchiya R, Harada N, Tsukasa T, et al. Longterm survivors after operation on carcinoma of the pancreas. Int J Pancreatol 1988; 3: 491-496.
155. Van Heerden JA. Pancreatic resection for carcinoma of the pancreas: Whipple versus total pancreatectomy- an institutional perspective. World J Surg 1984; 8: 880-888.
156. Van Heerden JA, McIlrath DC, Ilstrup DM, et al. Total pancreatectomy for ductal adenocarcinoma of the pancreas: an update. World J Surg 1988; 12: 658-662.
157. Verma IM, Vogt PK. Oncogenes: 20 years later (Meeting review). Genes Dev 1995; 9: 1289-1301.
158. Warshaw A, Swanson RS. Pancreatic cancer in 1988. Possibilities and probabilities. Ann Surg 1988; 208: 541-553.
159. Warshaw A, Fernandez del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-465.
160. Watanapa P, Williamson RCN. Surgical palliation for pancreatic cancer: developments during the past two decades. Br J Surg 1992; 79: 8-20.
161. Weger AR, Glaser KS, Schwab G, et al. Quantitative nuclear DNA content in fine needle aspirates of pancreatic cancer. Gut 1991; 32: 325-328.
162. Weinberg RA Oncogenes and multistep carcinogenesis, in: RA Weinberg, ed. Oncogenes and the molecular origins of cancer. New York: Cold Spring Harbor Laboratory Press, 1989: 307-326.
163. Westlin J-E, Andersson-Forsman C, Garske U, et al. Objective response after fractionated infusional brachytherapy of unresectable pancreatic adenocarcinoma. Cancer 1997; 80(suppl): 2743-2748.
164. Whelan AJ, Bautsch D, Goodfellone PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in CDKN2 tumour suppression gene. N Engl J Med 1995; 333: 975-977.
165. Williamson RCN. Pancreatic cancer: the greatest oncological challenge. BMJ 1988; 296: 445-446.
166. Wiman KG. The retinoblastoma gene: role in cell cycle control and cell differentiation. FASEB J 1993; 7: 2277-2284.
167. Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer Metastasis Rev 1992; 1: 95-103.
168. Yamaguchi K, Enjoji M. Carcinoma of the pancreas: a clinico-pathologic study of 96 cases with immunohistochemical observations. Jpn J Clin Oncol 1989; 19: 14-22.
169. Yamaguchi A, Ninomiya I, Ishida T, et al. Immunohistochemical detection of c-myc products in colorectal cancer and proliferative cell rate. Oncology 1992; 49: 40-44.
170. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of pancreas. 201 patients. Ann Surg 1995; 221: 721-731.
171. Yokoyama M, Yamanaka Y, Friess H, Buchler M, Korc M. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994; 14: 2477-2484.
172. Yoshimura T, Manabe T, Imamura et al. Flow cytometric analysis of nuclear DNA content of duct cell carcinoma of the pancreas. Cancer 1992; 70: 1069-1074.
173. Zhang SY, Ruggeri B, Agarwal P, Sorting AF, Obara T, Ura H, Namiki M, Klein Szanto AJ. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994; 118: 150-154.
174. Zinner MJ. Solid and papillary neoplasms of the pancreas. Surg Clin North Am 1995; 75: 1017-1024.